Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004196 · ClinicalTrials.gov registry record · Phase 3
Interferon Alfa-2b in Treating Patients With Melanoma and Early Lymph Node Metastasis
A Phase 3 study, sponsored by University of Alabama at Birmingham.
- Completed
- Registry status
- Phase 3
- Development phase
- 3,000
- Enrollment target
NCT00004196: Completed Phase 3 study, sponsored by University of Alabama at Birmingham.
NCT00004196 is a Phase 3 study that has completed, run by University of Alabama at Birmingham. The registered enrollment target is 3,000 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (289% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00004196, a Phase 3 study, has completed, sponsored by University of Alabama at Birmingham.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 3,000 participants
- Enrollment target
Study Summary
RATIONALE: Interferon alfa-2b may interfere with the growth of cancer cells. PURPOSE: Randomized phase III trial to study the effectiveness of interferon alfa-2b in treating patients who have melanoma with early lymph node metastasis.
Interventions
- BIOLOGICAL recombinant interferon alfa
- PROCEDURE lymphangiography
- DRUG Observation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,000 participants |
| Start Date | 1999-10 |
| Est. Completion | 2007-11 |
| Phase | Phase 3 |
What the finished NCT00004196 record still lists
NCT00004196 is an interventional study that assigns participants to a tested intervention. Its 3,000 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (289% higher).
The record links to 0 conditions, and to 3 interventions - of which recombinant interferon alfa is the first listed.
NCT00004196 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00004196 about?
NCT00004196 is a clinical study titled "Interferon Alfa-2b in Treating Patients With Melanoma and Early Lymph Node Metastasis". RATIONALE: Interferon alfa-2b may interfere with the growth of cancer cells. PURPOSE: Randomized phase III trial to study the effectiveness of interferon alfa-2b in treating patients who have melanoma with early lymph node metastasis.
What is the current status of trial NCT00004196?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 3,000 participants. The study started on 1999-10. Estimated completion is 2007-11.
What interventions are being tested in trial NCT00004196?
The interventions under investigation include: recombinant interferon alfa (BIOLOGICAL), lymphangiography (PROCEDURE), Observation (DRUG).
Who is sponsoring clinical trial NCT00004196?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00004196's enrollment target sits among peer trials
3,000 79th of 2000 higher than 1,921 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00004847 · 3,000 participants · Phase 1
Diagnosis of Pheochromocytoma
- NCT00478712 · 3,000 participants
Hirschsprung Disease Genetic Study
- NCT00579566 · 3,000 participants
Novel Biochemical and Molecular Determinants for Soft Tissue Sarcoma
- NCT00816114 · 3,000 participants
Chart Review Study of Chronic Myelogenous Leukemia (CML) Patients Treated With Imatinib Outside of a Clinical Trial
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia